HitGen(SH:688222)2023-10-30 06:36Group 1: Company Overview - Chengdu XianDao Pharmaceutical Development Co., Ltd. aims to become a world-class innovative biopharmaceutical company focused on small molecule and nucleic acid drug discovery and optimization [3] - The company has developed a DNA-encoded compound library (DEL) with over 1.2 trillion molecules, making it a leader in the DEL technology field [4] - Chengdu XianDao has multiple internal drug projects at various clinical and preclinical stages, with a focus on global markets including North America, Europe, Asia, Africa, and Oceania [5] Group 2: Financial Performance - In Q3 2023, the company achieved a revenue of CNY 90.08 million, a year-on-year increase of 13.38% [6] - For the first three quarters of 2023, total revenue reached approximately CNY 246 million, up 12.64% year-on-year [6] - The net profit attributable to shareholders for the first three quarters of 2023 was CNY 18.29 million, reflecting a significant increase of 75.35% compared to the previous year [6] Group 3: Cash Flow and Business Recovery - The operating cash flow for the first three quarters of 2023 was CNY 65.79 million, a substantial improvement from a negative cash flow of CNY -6.61 million in the same period last year [6] - The increase in cash flow is attributed to the recovery of core DEL-related business and improved sales collections [7] Group 4: Strategic Adjustments - The company has adjusted the exclusivity period for DEL library screening from three years to one year to increase potential order quantities and better utilize its extensive compound library [7][8] - This change is expected to enhance customer trust and engagement without affecting the intellectual property rights of the compounds screened [8] Group 5: New Service Offerings - Chengdu XianDao introduced "DEL For" and "DEL Plus" services aimed at early drug development, focusing on specific targets and integrating AI/ML for enhanced compound discovery [9][10] - The company has over 50 novel E3 ligase proteins available for direct customer orders, showcasing its commitment to innovative drug discovery [10] Group 6: Collaborations and Partnerships - In September 2023, the company's subsidiary Vernalis partnered with Pierre Fabre Laboratories to develop drug candidates targeting undisclosed tumor markers [11] - The collaboration with the Structural Genomics Consortium (SGC) aims to utilize DEL technology for screening new targets, contributing to the global open science initiative "Target 2035" [12]